Physician profile
Maqbool B Ali
NPI 1801874565
$2,437.90
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $793 · 2020: $312 · 2021: $719 · 2022: $363 · 2023: $134 · 2024: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $185.83 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $527.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $367.85 | 2019-2021 | |
| Astellas Pharma US INC | $296.99 | 2022-2024 | Veozah |
| Amgen INC. | $267.32 | 2019-2021 | |
| Pfizer INC. | $219.92 | 2019-2023 | |
| Esperion Therapeutics, INC. | $147.50 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $117.36 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $112.61 | 2022 | |
| Daiichi Sankyo INC. | $80.41 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $60.63 | 2020-2021 | |
| Ascend Therapeutics US, LLC | $49.82 | 2021 | |
| Lilly USA, LLC | $46.07 | 2019-2021 | |
| Lupin INC. | $27.50 | 2019-2020 | |
| Therapeuticsmd, INC. | $26.54 | 2019 | |
| Evofem Biosciences, INC. | $25.56 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $18.93 | 2021 | |
| Nestle Healthcare Nutrition INC. | $16.54 | 2022 | |
| Coopersurgical, INC. | $15.40 | 2021 | |
| Dysis Medical, INC. | $13.95 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maqbool Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.